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Eur J Vasc Endovasc Surg (2009) 37, 120e122CORRESPONDENCEEndovascular Repair of Aortic Transection can be
a Durable Treatment OptionWe enjoyed reading the paper by Mohan et al.1
Our experience in the endovascularmanagement of aortic
transection began in 1997. This patient was an 18-year old
male who on initial presentation underwent operative
management of both splenic and liver injuries, with the
diagnosis of aortic transection not made until 6 weeks after
the event. He subsequently underwent successful deploy-
ment of a Vanguard device (Boston Scientific, Natick, MA) via
an infrarenal conduit and has remained well during both
imaging and clinical follow up.
Although thisearly generationdevicewasnot thought tobe
durable it has performed well in the thoracic aorta for 11
years. Thismaybedue to the fact that this transectionwasnot
circumferential. It is possible that partial transections have
the ability heal and therefore the device is not subjected to
the same forces aswould be seen in a degenerative aneurysm.
Endovascular repair is so successful that it has become the
treatment of choice for aortic transection. The problem of
stent graft collapse will decrease with increasing experi-
ence, smaller stents and more compliant devices.
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a Durable Treatment OptionWe thank Messrs Clough and Taylor for their interest in our
paper.1 The case presented, highlights many of the difficul-
ties and challenges faced in this critically injured group of
patients, and it is without doubt that stent grafts should now
be the treatment of choice for thoracic aortic transections.
Questions of graft durability are still of concern in this young
patient cohort, and only time will provide the answers.
The pathology of thoracic aortic injury has been well
documented.2 While some aortic tears may heal over, they
are still at risk of chronic pseudoaneurysm formation, and
late rupture.3 The mechanical forces on the stent graft in
this condition may well be very different to that seen in
patients with established thoracic aneurysms, and this may
explain the longevity of the device used in their patient.
Despite the difficulties encountered with the early
generation commercially available endovascular devices in
aneurysmal disease, the Vanguard Device (Boston Scientific,
Natick, MA) has served this patient well.
We agree that continued evolution of the technique
will further decrease both patient and graft related
complications and provide further answers regarding graft
durability.
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Sir,
I write to congratulate the Authors and the Series Editor,
Professor Naylor, for an excellent article on the medico-
legal aspects of surgical intervention. In my view, this
article should become compulsory reading for Consultants
and Trainees in all surgical specialties. I do hope that this
article will also be read by Lawyers involved with
medico-legal work. Perhaps the article could be re-pub-
lished in a Legal Journal? There should be no impediment
to dual publication as the audiences of the two Journals
are completely different, as long as copyright is
acknowledged.
I disagree with the Authors in only one of their state-
ments. That is that: ‘‘We do not support the claim that
with any new surgical procedure a randomised trial should
begin with the first patient as this could potentially stifle
advancement in surgical technique.’’
I agree that a randomised trial cannot take place until
a new surgical procedureor device has beendeveloped to the
point where a trial seems feasible. However, I disagree that
amonitoring or audit period should bea requirement to enter
a trial. The Authors themselves state that: ‘‘The ‘‘learning
curve’’ needs careful monitoring to ensure safety and effi-
cacy.’’ The best way to monitor this is within the confines of
a randomised controlled trial. Relying on self-reporting or
registries to monitor the ‘‘learning curves’’ can lead to over-
optimistic results caused by a selection bias. Investigators
worry that including the ‘‘learning curve’’ in a randomised
trial might damage their results. This is not the case if
a ‘Tracker Trial’ methodology is used where the results areDOI of original article: 10.1016/j.ejvs.2008.05.006.analysed in a temporal fashion. The data generated from the
early part of such a trial can give valuable information about
the generalisability of the technique, if it subsequently
becomes widely adopted.
I was also disappointed that the Authors did not address
the dilemma posed during the period after a trial ends and
before the results are known. What should a Clinician do
during this time period? The obvious solution is for trials to
include continued funding for randomisation during this
period in their trial design. Clinicians and patients then do
not have to make a difficult decision about which treat-
ment to choose before the results are known and the
additional data can be subsequently added to the main
trial data at a later date.
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‘‘Learning curve’’ of innovative interventions become
questionable practice?’’Sir
We would like to thank Professor J. D. Beard for his
comments and observations on our recent publication
‘‘When does the ‘‘learning curve’’ of innovative interven-
tions become questionable practice? Eur J Vasc Endovasc
Surg 2008; 36: 253e257. These comments are warmly
accepted and provide a welcome insight from a clinical
perspective.
The authors acknowledge Professor Beard’s suggestion
that use of a Tracker Trial methodology might be of benefit
from a clinical viewpoint. We suggest, however, that this
method would be of little benefit when viewed on legal and
ethical grounds, particularly when considered from the
patient perspective.
We agree that in principle, the Tracker Trial method-
ology could offer a useful means of preserving clinical
equipoise and to assist in the early identification of the
surgeon whose performance is not up to the required
standard. This will not, however, be of any benefit to the
first recipients of the new technique. Irrespective of
additional safeguards, proposed in Tracker TrialDOI of original article: 10.1016/j.ejvs.2008.09.021.
